In a nutshell This phase 2 clinical trial will test the effectiveness of a combination treatment, consisting of ibrutinib (Imbruvica), fludarabine (Fludara), cyclophosphamide (Cytoxan), and obinutuzumab (Gazyva), in treating chronic lymphocytic leukemia (CLL). The primary outcome will be measured by the response to treatment. This trial is being...
Read More
In a nutshell This phase 2/3 clinical trial will test the effectiveness of gilteritinib (ASP2215) with or without azacitidine (Vidaza) versus azacitidine alone in treating newly diagnosed acute myeloid leukemia (AML) patients with FLT3 mutation. The primary outcome will be measured by the overall survival. The details ASP2215 is is an...
Read More
In a nutshell This study examined stem cell transplant outcomes across acute myeloid leukemia (AML) patients with different disease status. Researchers reported superior survival after a stem cell transplant among patients in second complete remission. Some background Stem cell transplantation is considered the most effective therapy for...
Read More
In a nutshell This study aimed to investigate atrial fibrillation as a side effect of ibrutinib (imbruvica) in chronic lymphocytic leukemia. This study concluded that atrial fibrillation is a common side effect associated with ibrutinib use in patients with chronic lymphocytic leukemia. Some background Chronic lymphocytic leukemia (CLL)...
Read MoreIn a nutshell This study examined the order of treatment with ibrutinib (Imbruvica), idelalisib (Zydelig), and venetoclax (ABT-199) for chronic lymphocytic leukemia (CLL). Researchers concluded that ibrutinib appears superior to idelalisib as first treatment. Some background Early studies are reporting promising results with targeted therapies for...
Read More
In a nutshell This study aimed to investigate the outcomes of hematopoietic cell transplantation for primary refractory acute lymphoblastic leukemia. This study concluded that hematopoietic cell transplantation is of benefit to patients with primary refractory acute lymphoblastic leukemia. Some background Acute lymphoblastic leukemia (ALL)...
Read More
In a nutshell This study examined the effectiveness of different doses of nilotinib (Tasigna) in patients with newly diagnosed chronic myeloid leukemia in chronic phase. This study concluded that nilotinib was safe and effective in treating chronic myeloid leukemia. Some background Chronic myeloid leukemia is a cancer where the...
Read More
In a nutshell This study examined the benefits of adding midostaurin (Rydapt) to standard chemotherapy in patients with acute myeloid leukemia (AML) and a genetic abnormality on the FLT3 gene. Authors reported improved treatment outcomes when AML patients with the FLT3 mutation were also treated with midostaurin. Some background AML is cancer of...
Read More
In a nutshell This study explored whether a higher starting dose of imatinib (Gleevac) is safe and effective as a first-line treatment for chronic myeloid leukemia (CML). This study concluded that response rates were similar between the higher and lower dose after 1 year, but the response occurred earlier with the higher dose. Some background...
Read More
In a nutshell This study examined the effectiveness of sorafenib (Nexavar) in acute myeloid leukemia (AML) patients younger than age 60. The study concluded that sorafenib was effective but increased negative side effects. Some background Targeted therapies are treatments that block certain proteins involved in cancer growth. Sorafenib is a...
Read More
In a nutshell This study examined the effect of dose reductions or interruptions on the effectiveness of dasatinib (Sprycel) and nilotinib (Tasigna). The authors concluded that dose reductions or treatment breaks did not affect response or survival rates in chronic myeloid leukemia (CML) patients. Some background The tyrosine kinase inhibitor...
Read More
In a nutshell This study, from 2009, examined the effectiveness of increasing the dose of daunorubicin (Cerubidine) in acute myeloid leukemia (AML). This study concluded that a higher dose improved remission rates (no sign of disease) and 2-year survival rates. Some background The standard induction therapy (treatment to induce remission) for AML...
Read More
